I
IMMP
Immutep
1.71
-0.06-3.39%Opening14:26 08/25 EDT
OPEN/PREV CLOSE1.750/1.770
TODAY RANGE1.670-1.750
VOL75.60K
MARKET CAP249.73M
52 WEEK RANGE1.320-2.720
AVG VOL (3M)86.54K
% TURNOVER0.05%
TURNOVER--
P/E (TTM)-8.3578
% RANGE4.52%
EPS(TTM)-0.2046
P/E(FORWARD)-7.1473
P/B2.321
BVPS0.7367
DIVIDEND--
P/S3,420.00
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP249.70M
SHARES OUTSTANDING146.04M
NEXT EARNINGS08/25-08/26
FREE FLOAT146.02M
LOT SIZE1
EX-DATE12/28/2016
News
Press Releases
Financial Reports
Profile
TipRanks·08/07 10:52
Immutep Gains FDA Support for Eftilagimod Alfa in Cancer Treatment
TipRanks·08/06 16:05
Immutep’s Strategic Advances and Promising Clinical Data Drive Buy Rating
TipRanks·08/06 02:15
Canaccord Genuity Sticks to Its Buy Rating for Immutep Ltd (PRRUF)
TipRanks·08/05 12:35
Immutep receives FDA feedback on clinical development of eftilagimod alfa
TipRanks·07/31 10:42
Immutep Reports Significant Progress in Cancer and Autoimmune Trials
TipRanks·07/30 12:31
Immutep reports Q4 cash receipts from customers A$6,000
TipRanks·07/21 01:55
Wilsons Reaffirms Their Buy Rating on Immutep Ltd (PRRUF)
TipRanks·06/24 10:31
Immutep Reports Promising Phase I Results for IMP761 in Autoimmune Diseases
TipRanks·06/23 18:01
Immutep announces initial efficacy data from Phase I study of IMP761
Same Industry
Name/Symbol
Change%
Price
Contact Us
Contact Number : +852 3852 8500Service Email : service@webull.hkBusiness Cooperation : marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2025 Webull Securities Limited. All rights reserved.